Advertisement

Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study

Published:January 21, 2021DOI:https://doi.org/10.1016/j.ejca.2020.12.026

      Highlights

      • Large-scale real-world data showed longer progression-free survival of alectinib than crizotinib.
      • But, propensity score analysis of overall survival could not show the superiority of alectinib.
      • Poor responders to crizotinib had poorer response also to alectinib.
      • Ceritinib or lorlatinib showed activity even after crizotinib or alectinib therapy.
      • Meanwhile, immunotherapy could not show clinical benefit in our data.

      Abstract

      Background

      The data of sequential therapy of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in clinical practice have been limited.

      Methods

      We reviewed the clinical data of patients with ALK-rearranged non-small cell lung cancer who received crizotinib (CRZ) or alectinib (ALEC) between May 2012 and December 2016. Patients were divided into two groups based on the first-administered ALK-TKI, the CRZ or ALEC group. The combined time-to-treatment failure (TTF) was defined as the sum of the ‘TTF of CRZ’ plus the ‘TTF of ALEC’ if patients were treated with CRZ followed by ALEC in the CRZ group. The primary end-point is the comparison between the combined TTF and the TTF of ALEC in the ALEC group.

      Results

      Of 864 patients enrolled from 61 institutions, 840 patients were analysed. There were 535 of 305 patients in the CRZ/ALEC groups. The combined TTF in the CRZ group was significantly longer than TTF in the ALEC group (median, 34.4 versus 27.2 months; hazard ratio [HR], 0.709; P = 0.0044). However, there was no significant difference in overall survival (OS) between the patients who received ALEC after CRZ in the CRZ group and the patients in the ALEC group (median, 88.4 months versus. not reached; HR, 1.048; P = 0.7770). In the whole population, the CRZ group had a significantly shorter OS than the ALEC group (median, 53.6 months versus not reached; HR, 1.821, P < 0.0001).

      Conclusion

      The combined TTF in the CRZ group was significantly longer than the TTF in the ALEC group; however, OS benefit of sequential therapy against ALEC as the first ALK-TKI was not shown.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ettinger D.S.
        • Aisner D.L.
        • Wood D.E.
        • et al.
        NCCN guidelines insights: non-small cell lung cancer, version 5.2018.
        J Natl Compr Canc Netw : J Natl Compr Canc Netw. 2018; 16: 807-821
        • Planchard D.
        • Popat S.
        • Kerr K.
        • et al.
        Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol : official journal of the European Society for Medical Oncology. 2019; 30: 863-870
        • Solomon B.J.
        • Mok T.
        • Kim D.W.
        • et al.
        First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
        N Engl J Med. 2014; 371: 2167-2177
        • Shaw A.T.
        • Gandhi L.
        • Gadgeel S.
        • et al.
        Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
        Lancet Oncol. 2016; 17: 234-242
        • Seto T.
        • Kiura K.
        • Nishio M.
        • et al.
        CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study.
        Lancet Oncol. 2013; 14: 590-598
        • Zhou C.
        • Kim S.-W.
        • Reungwetwattana T.
        • et al.
        Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
        The Lancet Respiratory Medicine. 2019; 7: 437-446
        • Hida T.
        • Nokihara H.
        • Kondo M.
        • et al.
        Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
        Lancet. 2017; 390: 29-39
        • Peters S.
        • Camidge D.R.
        • Shaw A.T.
        • et al.
        Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer.
        N Engl J Med. 2017; 377: 829-838
        • Camidge D.R.
        • Dziadziuszko R.
        • Peters S.
        • et al.
        Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study.
        J Thorac Oncol. 2019; 14: 1233-1243
        • Mok T.
        • Camidge D.R.
        • Gadgeel S.M.
        • et al.
        Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
        Ann Oncol. 2020; 31: 1056-1064
        • Ito K.
        • Hataji O.
        • Kobayashi H.
        • et al.
        Sequential therapy with crizotinib and alectinib in ALK-rearranged non-small cell lung cancer-A multicenter retrospective study.
        J Thorac Oncol. 2017; 12: 390-396
        • Fontana D.
        • Ceccon M.
        • Gambacorti-Passerini C.
        • et al.
        Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
        Cancer Med. 2015; 4: 953-965
        • Gainor J.F.
        • Dardaei L.
        • Yoda S.
        • et al.
        Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer.
        Canc Discov. 2016; 6: 1118-1133
        • Shaw A.T.
        • Solomon B.J.
        • Besse B.
        • et al.
        ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer.
        J Clin Oncol. 2019; 37: 1370-1379
        • Christopoulos P.
        • Budczies J.
        • Kirchner M.
        • et al.
        Defining molecular risk in ALK(+) NSCLC.
        Oncotarget. 2019; 10: 3093-3103
        • Christopoulos P.
        • Endris V.
        • Bozorgmehr F.
        • et al.
        EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+) non-small cell lung cancer.
        Int J Canc. 2018; 142: 2589-2598
        • Kron A.
        • Alidousty C.
        • Scheffler M.
        • et al.
        Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
        Ann Oncol. 2018; 29: 2068-2075
        • Christopoulos P.
        • Kirchner M.
        • Bozorgmehr F.
        • et al.
        Identification of a highly lethal V3(+) TP53(+) subset in ALK(+) lung adenocarcinoma.
        Int J Canc. 2019; 144: 190-199